Lapatinib is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
Western Union, Cheque, Cash in Advance (CID), Cash Advance (CA), Cash on Delivery (COD)
Main Export Market(s)
Western Europe, Eastern Europe, South America, Central America, Australia, Asia